Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is a promising investment due to their strong management team, research partnerships, and potential best-in-class drug for neuropsychiatric disorders with extended patent protection. While their current valuation is low, investors should consider the potential risks and a need for further research on product effectiveness and possible side effects.

Bears say

MapLight Therapeutics is a clinical-stage biopharmaceutical company with a negative outlook due to the early-stage and speculative nature of its drug products, potential for failure in clinical trials, and competition in the neuropsychiatric market. While the company's therapeutic approach targeting neural circuits shows promise, its lack of a proven track record and significant financial resources could be concerning to investors. Additionally, without any approved drugs on the market and a limited pipeline, the company's revenue potential remains uncertain.

MPLT has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 6 analysts, MPLT has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.